These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 15151456)

  • 21. Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls.
    Elmslie JL; Porter RJ; Joyce PR; Hunt PJ; Shand BI; Scott RS
    Aust N Z J Psychiatry; 2009 Jan; 43(1):53-60. PubMed ID: 19085528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia.
    Barnett AH; Mackin P; Chaudhry I; Farooqi A; Gadsby R; Heald A; Hill J; Millar H; Peveler R; Rees A; Singh V; Taylor D; Vora J; Jones PB
    J Psychopharmacol; 2007 Jun; 21(4):357-73. PubMed ID: 17656425
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Medication-induced weight gain and dyslipidemia in patients with schizophrenia.
    Fenton WS; Chavez MR
    Am J Psychiatry; 2006 Oct; 163(10):1697-704; quiz 1858-9. PubMed ID: 17012676
    [No Abstract]   [Full Text] [Related]  

  • 25. Metabolic syndrome: epidemiology and consequences.
    Sacks FM
    J Clin Psychiatry; 2004; 65 Suppl 18():3-12. PubMed ID: 15600380
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Screening of adults with schizophrenia for metabolic complications caused by atypical antipsychotics].
    Cohen D
    Tijdschr Psychiatr; 2010; 52(2):111-5. PubMed ID: 20146182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interventions to reduce weight gain in schizophrenia.
    Faulkner G; Cohn T; Remington G
    Schizophr Bull; 2007 May; 33(3):654-6. PubMed ID: 17449900
    [No Abstract]   [Full Text] [Related]  

  • 29. Antipsychotic induced weight gain in schizophrenia:mechanisms and management.
    Rege S
    Aust N Z J Psychiatry; 2008 May; 42(5):369-81. PubMed ID: 18473255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biological perspectives. Metabolic syndrome: schizophrenia and atypical antipsychotics.
    Keltner NL
    Perspect Psychiatr Care; 2006 Aug; 42(3):204-7. PubMed ID: 16916424
    [No Abstract]   [Full Text] [Related]  

  • 31. Can metformin or rosiglitazone reduce metabolic side effects associated with atypical antipsychotics?
    Housel AK; Waterbury N; Argo TR
    Issues Ment Health Nurs; 2009 Dec; 30(12):803-5. PubMed ID: 19916816
    [No Abstract]   [Full Text] [Related]  

  • 32. Obesity and metabolic syndrome in a psychiatric rehabilitation service.
    Tirupati S; Chua LE
    Aust N Z J Psychiatry; 2007 Jul; 41(7):606-10. PubMed ID: 17558623
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association of weight gain and metabolic syndrome in patients taking clozapine: an 8-year cohort study.
    Bai YM; Lin CC; Chen JY; Chen TT; Su TP; Chou P
    J Clin Psychiatry; 2011 Jun; 72(6):751-6. PubMed ID: 21208584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessing cardiovascular risks versus clinical benefits of atypical antipsychotic drug treatment.
    Meltzer HY; Davidson M; Glassman AH; Vieweg WV
    J Clin Psychiatry; 2002; 63 Suppl 9():25-9. PubMed ID: 12088173
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Antipsychotic-induced weight gain--pharmacogenetic studies].
    Olajossy-Hilkesberger L; Godlewska B; Marmurowska-Michałowskal H; Olajossy M; Landowski J
    Psychiatr Pol; 2006; 40(5):1009-20. PubMed ID: 17217242
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of antipsychotic-induced weight gain.
    McIntyre RS; Mancini DA; Basile VS
    J Clin Psychiatry; 2001; 62 Suppl 23():23-9. PubMed ID: 11603882
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents.
    Henderson DC
    J Clin Psychiatry; 2001; 62 Suppl 27():10-4; discussion 40-1. PubMed ID: 11806484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities.
    Henderson DC
    J Clin Psychiatry; 2001; 62 Suppl 23():39-44. PubMed ID: 11603884
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic and endocrine disturbances in psychiatric disorders: a multidisciplinary approach to appropriate atypical antipsychotic utilization.
    Masand PS; Culpepper L; Henderson D; Lee S; Littrell K; Newcomer JW; Rasgon N
    CNS Spectr; 2005 Oct; 10(10):suppl14 1-15. PubMed ID: 16404802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Metabolic and cardiovascular adverse effects of modern antipsychotic agents].
    Andreassen OA; Bentsen H
    Tidsskr Nor Laegeforen; 2004 Jan; 124(2):181-2. PubMed ID: 14743232
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.